Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fokko J Bosker

Showing results (1-10 of 45) with videos related to

Pageof 5
Sort By:
The British Journal of Psychiatry : the Journal of Mental Science|November 3, 2016
Authors' replyRobert A Schoevers, Fokko J Bosker
Human Psychopharmacology|October 31, 2002
Serotonergic drugs in the treatment of depressive and anxiety disordersJohan A. Den Boer, Fokko J. Bosker, Bernhard R. Slaap
BMC Psychiatry|September 5, 2018
N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trialChenghao Yang, Fokko J Bosker, Jie Li, et al.
European Journal of Pharmacology|November 26, 2002
Effect of 5-HT1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brainMinke E Jongsma, Jantiena B Sebens, Fokko J Bosker, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 21, 2020
Can loss of agency and oppositional perturbation associated with antidepressant monotherapy and low-fidelity psychological treatment dilute the benefits of guideline-consistent depression treatment at the population level?Johan Ormel, Fokko J Bosker, Steven D Hollon, et al.
Journal of Affective Disorders|July 30, 2019
Inflammatory markers and treatment outcome in treatment resistant depression: A systematic reviewChenghao Yang, Klaas J Wardenaar, Fokko J Bosker, et al.
Current Pharmaceutical Design|May 12, 2004
PET imaging of beta-adrenoceptors in human brain: a realistic goal or a mirage?Aren van Waarde, Willem Vaalburg, Petra Doze, et al.
The International Journal of Neuropsychopharmacology|January 6, 2010
Oxazepam and temazepam attenuate paroxetine-induced elevation of serotonin levels in guinea-pig hippocampusThomas I F H Cremers, Eliyahu Dremencov, Fokko J Bosker, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 13, 2012
Urinary norepinephrine and epinephrine excretion rates are heritable, but not associated with office and ambulatory blood pressureFokko J Bosker, Ting Wu, Anatoliy Gladkevich, et al.
Molecular Genetics & Genomic Medicine|August 6, 2021
The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder: A case-control association studyChenghao Yang, Ilja M Nolte, Yanyan Ma, et al.
Pageof 5

Showing results (1-10 of 45) with videos related to

Sort By:
Pageof 5
The British Journal of Psychiatry : the Journal of Mental Science|November 3, 2016
Authors' replyRobert A Schoevers, Fokko J Bosker
Human Psychopharmacology|October 31, 2002
Serotonergic drugs in the treatment of depressive and anxiety disordersJohan A. Den Boer, Fokko J. Bosker, Bernhard R. Slaap
BMC Psychiatry|September 5, 2018
N-acetylcysteine as add-on to antidepressant medication in therapy refractory major depressive disorder patients with increased inflammatory activity: study protocol of a double-blind randomized placebo-controlled trialChenghao Yang, Fokko J Bosker, Jie Li, et al.
European Journal of Pharmacology|November 26, 2002
Effect of 5-HT1A receptor-mediated serotonin augmentation on Fos immunoreactivity in rat brainMinke E Jongsma, Jantiena B Sebens, Fokko J Bosker, et al.
European Psychiatry : the Journal of the Association of European Psychiatrists|September 21, 2020
Can loss of agency and oppositional perturbation associated with antidepressant monotherapy and low-fidelity psychological treatment dilute the benefits of guideline-consistent depression treatment at the population level?Johan Ormel, Fokko J Bosker, Steven D Hollon, et al.
Journal of Affective Disorders|July 30, 2019
Inflammatory markers and treatment outcome in treatment resistant depression: A systematic reviewChenghao Yang, Klaas J Wardenaar, Fokko J Bosker, et al.
Current Pharmaceutical Design|May 12, 2004
PET imaging of beta-adrenoceptors in human brain: a realistic goal or a mirage?Aren van Waarde, Willem Vaalburg, Petra Doze, et al.
The International Journal of Neuropsychopharmacology|January 6, 2010
Oxazepam and temazepam attenuate paroxetine-induced elevation of serotonin levels in guinea-pig hippocampusThomas I F H Cremers, Eliyahu Dremencov, Fokko J Bosker, et al.
Hypertension Research : Official Journal of the Japanese Society of Hypertension|July 13, 2012
Urinary norepinephrine and epinephrine excretion rates are heritable, but not associated with office and ambulatory blood pressureFokko J Bosker, Ting Wu, Anatoliy Gladkevich, et al.
Molecular Genetics & Genomic Medicine|August 6, 2021
The associations of CNR1 SNPs and haplotypes with vulnerability and treatment response phenotypes in Han Chinese with major depressive disorder: A case-control association studyChenghao Yang, Ilja M Nolte, Yanyan Ma, et al.
Pageof 5